jadebiosciences
Senior Clinical Scientist
At a Glance
- Location
- Boston; Remote; San Francisco; Vancouver
- Work Regime
- remote
- Experience
- 5–8 years
- Compensation
- r candidates for this role is $175,000 - $190,000 . The final salary offered wi
- Posted
- 2026-07-24T20:44:10-04:00
Key Requirements
Domain Knowledge
- Biotech
- Clinical
- Pharmaceutical
- Regulatory
Requirements
Minimum 5–8 years of clinical research experience in the biotechnology, pharmaceutical, or CRO industry.
Experience supporting Phase 2 and/or Phase 3 clinical trials.
Strong understanding of clinical trial design, clinical data review, and drug development.
Experience reviewing clinical data and collaborating with biostatistics and data management teams.
Experience with global multicenter clinical trials.
Prior involvement in regulatory submissions and health authority interactions.
Compensation & Benefits
$175,000 - $190,000
.
The final salary offered will depend on several factors, which may include, but not limited to, relevant years of experience, educational background, and geography.
As part of the I-9 verification of authorization to work in the United States, Jade Bioscience participates in E-Verify. To learn more about E-Verify please review this
poster
.
Responsibilities
Senior Clinical Scientist
programs in nephrology
with a focus on rare or immune-mediated kidney diseases
This individual will play a key role in translating clinical strategy into high-quality execution of
This is an exciting opportunity to join a growing biotechnology company where individual contributions have
, and takes ownership of key deliverables.
About the Company
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody candidate, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit
JadeBiosciences.com
.